Navigation Links
HCM Announces Substantial Growth in 2007
Date:2/26/2008

Attracts new talent to key positions

BURLINGTON, Mass., Feb. 26 /PRNewswire/ -- Hyaluron Contract Manufacturing (HCM), a leading provider of pharmaceutical development services, continued to expand its business in 2007 with revenues increasing greater than 75 percent and staffing increasing greater than 60 percent to support past and anticipated future growth. Additionally, HCM acquired additional space at its Burlington MA facility to expand its analytical chemistry, microbiology and engineering laboratories as well as to provide additional manufacturing capacity.

"We are very proud of our recent growth," Shawn Kinney, president of HCM states. "It's a reflection of our ongoing commitment to continuous improvements and to providing high quality products and services to our customers."

HCM has continued to strengthen its management team with the appointment of Susan McNamara to the newly created position of Director of Quality and Christopher Paolillo to the position of Director of Contract Administration and Legal Affairs and other key hires.

Susan McNamara has over seventeen years of experience in the biotechnology industry, bringing novel recombinant proteins into clinical and commercial production. Before joining HCM, McNamara was Associate Director, QC Microbiology at Wyeth Biotech. Prior to that, McNamara was employed by Fisons Pharmaceuticals and SmithKline.

Christopher Paolillo has over twenty-seven years of experience as corporate counsel and as an attorney in private practice and with the office of Air Force Judge Advocate. He brings to HCM substantial experience in contracts, licensing, intellectual property, and commercial transactions. Prior to HCM, Paolillo was employed by ACI Worldwide (formerly P&H Solutions) as Vice President and Corporate Counsel.

Located in Burlington, MA, HCM has been offering aseptic formulation and filling services to biotechnology and pharmaceutical companies. At the core of HCM's business is a commitment to quality, regulatory compliance and on-time delivery.
For further information, visit http://www.hyaluron.com

Contact: Claudio Tracanna

Office Phone: 781-270-7900 x 114

Cell Phone: 781-443-2850

Email: ctracanna@hyaluron.com


'/>"/>
SOURCE Hyaluron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NPS Pharmaceuticals Announces Senior Management Changes
2. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
3. Boston Scientific Announces Addition to Clinical Sciences Organization
4. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
7. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
8. Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
9. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
10. Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):